10-QPeriod: Q2 FY2014

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q2 Ended Jun 30, 2014

Filed July 31, 2014For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported a significant net loss for the three and six months ended June 30, 2014, primarily driven by high research and development expenses. Total revenues declined substantially year-over-year, largely due to a sharp decrease in INCIVEK product revenues, though this was partially offset by growth in KALYDECO net product revenues. The company has made progress on its key pipeline drug, lumacaftor in combination with ivacaftor, with positive Phase 3 trial data and plans to submit for regulatory approval. Despite the current net loss, Vertex Pharmaceuticals maintains a substantial cash position, bolstered by a recent $300 million term loan, which is expected to fund operations for at least the next twelve months. Investor focus should be on the upcoming regulatory submission for lumacaftor/ivacaftor, which represents the company's primary growth driver. The company's ability to navigate the approval process and subsequent market penetration will be critical for future profitability. Continued growth in KALYDECO sales and effective management of R&D spending are also key areas to monitor.

Financial Highlights

48 data points
Beta

Revenue

$138.42M

93.0% Gross Margin

Net Income

-$159.38M

-115.1% Net Margin

EPS (Diluted)

$-0.68

Total Assets

$2.12B

Cash & Equivalents

$420.56M

Free Cash Flow

-$139.62M

Financial Statements
Beta
Revenue$138.42M
Cost of Revenue$9.65M
Gross Profit$128.77M
R&D Expenses$224.49M
SG&A Expenses$77.45M
Operating Expenses$318.96M
Operating Income-$180.54M
Net Income-$159.38M
EPS (Basic)$-0.68
EPS (Diluted)$-0.68
Shares Outstanding (Basic)233.81M
Shares Outstanding (Diluted)233.81M

Key Highlights

  • 1Net loss attributable to Vertex was $159.4 million for Q2 2014, a significant increase from a $57.2 million loss in Q2 2013.
  • 2Total revenues decreased by 55% year-over-year to $138.4 million in Q2 2014, primarily due to a steep decline in INCIVEK sales.
  • 3KALYDECO product revenues showed strong growth, increasing by 14% year-over-year in Q2 2014 to $113.1 million.
  • 4The company announced positive Phase 3 trial results for lumacaftor in combination with ivacaftor and plans to submit for regulatory approval in Q4 2014.
  • 5Research and development expenses remained high, totaling $224.8 million in Q2 2014, a slight increase of 1% year-over-year.
  • 6Vertex Pharmaceuticals secured a $300 million senior secured term loan in July 2014, providing a significant liquidity boost.
  • 7The company's cash, cash equivalents, and marketable securities stood at $1.22 billion as of June 30, 2014.

Frequently Asked Questions

The primary reasons for Vertex's net loss are substantial research and development expenses and a significant decrease in product revenues, particularly from INCIVEK, which was partially offset by growth in KALYDECO revenues and a one-time non-operational gain.

Vertex Pharmaceuticals announced positive Phase 3 clinical trial data for lumacaftor in combination with ivacaftor and plans to submit New Drug Applications (NDAs) to the FDA and Marketing Authorization Applications (MAAs) to the EMA in the fourth quarter of 2014. This combination is viewed as a significant growth driver for the company.

KALYDECO demonstrated strong performance with a 14% year-over-year increase in net product revenues for Q2 2014, reaching $113.1 million. Future growth is dependent on expanding market reimbursement and potential label expansions.

As of June 30, 2014, Vertex had $1.22 billion in cash, cash equivalents, and marketable securities. The company also secured a $300 million term loan in July 2014. Management believes these resources, combined with KALYDECO revenues, will be sufficient to fund operations for at least the next twelve months.